atugen Aktiengesellschaft

Atugen AG is a technology leader in disease pathway elucidation. Building on successful high profile collaborations, we are positioned to take advantage of the industry's need to unravel the function of genes and to dissect signal transduction pathways.

We offer proprietary KnockDown™ technologies such as antisense molecules (so called GeneBlocs®), improved synthetic siRNA, vector expression systems for siRNA and ribozymes, and superior transfection reagents.

Further Information: http://www.atugen.com